Grace Halsey

Obesity rates in states where it has leveled at 35% decreased for the first time but report authors warn the progress is limited and at risk due to federal budget cuts.

The Frist Clinic clinician said that technical difficulty is not impeding CGM uptake in primary care. "The real limitation is they just haven't done it before."

A multidisciplinary lung cancer screening program significantly boosts screening rates, ensuring timely follow-ups and early diagnoses for eligible patients.

The Menopause Society 2025 Annual Meeting, Oct 21-25, in Orlando, will focus on optimizing women's health and longevity at menopause and beyond. Highlights here.

Your daily dose of the clinical news you may have missed.

Highlights include size-based surveillance protocols, referral timing, cardiovascular risk reduction, and coordination with vascular surgery.

Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.

A study reveals that starting benzodiazepines or antipsychotics in hospice patients with dementia significantly increases 180-day mortality, urging careful prescribing.

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.

Your daily dose of the clinical news you may have missed.

A large Australian study found that training primary care physicians increased long-term LARC use, reduced unintended pregnancies, and improved reproductive health outcomes.

Shared decision-making for COVID-19 vaccines will widen disparities, said Moore, as those already skeptical or with limited access will likely opt out.

Step-by-step treatment protocol for upper airway cough syndrome including nasal steroids, antihistamines, and proper administration technique.

An 18-year multicohort study found that smokers who quit even in later life showed 20% slower memory decline vs those who continued to smoke.

FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.

Managing post–MI distress is no longer optional—it’s essential to comprehensive cardiac recovery, according to a new AHA statement.

Your daily dose of the clinical news you may have missed.

Emergency medicine physician Kabiul Haque, MD, discusses USPSTF screening guidelines for abdominal aortic aneurysm.

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.

Kabiul Haque, MD, a family medicine physician, shares his four-pillar approach to preventing PAD progression.

Based on the PREVENT algorithm's estimates of 10-year ASCVD risk, 4.2 million adults may need to be reevaluated for aspirin discontinuation, authors reported.

New research reveals GLP-1 receptor agonists may alter PET-CT scan interpretations, highlighting the need for updated guidelines in oncological imaging.

Roche's Elecsys pTau181 test has a 97.9% negative predictive value to rule out amyloid pathology, which will improve referral decisions and expedite treatment.

New global WHO data show escalating resistance in key bacterial pathogens, threatening frontline antibiotics and narrowing treatment options worldwide.

Vega considers the impact of recent changes in immunization policy on trust not just among patients but among clinicians as well. It all threatens good patient care, he said.

Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.

Clinical and real-world data are on deck for lumateperone, seltorexant, and esketamine to treat major depressive disorder and treatment-resistant depression.

OLPs did not affect migraine frequency but did subjectively improve QoL, with authors noting they may have a role as a supportive treatment option for select patients.

Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.